Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT02 in advanced malignant melanoma
NCT07107178Phase 1Not yet recruiting
- Sponsor
- BioTroy Therapeutics
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of BT02 in Malignant Melanoma (MM), sponsored by BioTroy Therapeutics. Primary endpoints: Adverse events, Dose limited toxicity and 2 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
BT02
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT07107178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107178.